Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $69,200.00 in Stock

Posted by Stanley Muller on Aug 8th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $6.92, for a total value of $69,200.00. Following the sale, the insider owned 600,887 shares of the company’s stock, valued at approximately $4,158,138.04. This represents a 1.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00.
On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total transaction of $21,000.00.
On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $7.71 on Friday. The company has a market cap of $646.79 million, a PE ratio of -6.70 and a beta of 0.96. SOPHiA GENETICS SA has a 12 month low of $2.96 and a 12 month high of $7.86. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 1.90. The company has a 50-day simple moving average of $5.63 and a 200-day simple moving average of $5.15.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, equities analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Perkins Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $49,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter worth $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the 1st quarter worth $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SOPH. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research upped their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright increased their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Report on SOPHiA GENETICS

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.